title: Effects of dietary fat modification on oxidative stress and inflammatory markers in the LIPGENE study.
abstract: Subjects with the metabolic syndrome (MetS) have enhanced oxidative stress and inflammation. Dietary fat quality has been proposed to be implicated in these conditions. We investigated the impact of four diets distinct in fat quantity and quality on 8-iso-PGF2α (a major F2-isoprostane and oxidative stress indicator), 15-keto-13,14-dihydro-PGF2α (15-keto-dihydro-PGF2α, a major PGF2α metabolite and marker of cyclooxygenase-mediated inflammation) and C-reactive protein (CRP). In a 12-week parallel multicentre dietary intervention study (LIPGENE), 417 volunteers with the MetS were randomly assigned to one of the four diets: two high-fat diets (38 % energy (%E)) rich in SFA or MUFA and two low-fat high-complex carbohydrate diets (28 %E) with (LFHCC n-3) or without (LFHCC) 1·24 g/d of very long chain n-3 fatty acid supplementation. Urinary levels of 8-iso-PGF2α and 15-keto-dihydro-PGF2α were determined by RIA and adjusted for urinary creatinine levels. Serum concentration of CRP was measured by ELISA. Neither concentrations of 8-iso-PGF2α and 15-keto-dihydro-PGF2α nor those of CRP differed between diet groups at baseline (P>0·07) or at the end of the study (P>0·44). Also, no differences in changes of the markers were observed between the diet groups (8-iso-PGF2α, P = 0·83; 15-keto-dihydro-PGF2α, P = 0·45; and CRP, P = 0·97). In conclusion, a 12-week dietary fat modification did not affect the investigated markers of oxidative stress and inflammation among subjects with the MetS in the LIPGENE study.
authors.affiliation: Department of Public Health and Caring Sciences/Clinical Nutrition and Metabolism, Uppsala University, Uppsala Science Park, 75185 Uppsala, Sweden.
authors.forename: Helena
authors.initials: H
authors.lastname: Petersson
authors.forename: Ulf
authors.initials: U
authors.lastname: Risérus
authors.forename: Jolene
authors.initials: J
authors.lastname: McMonagle
authors.forename: Hanne L
authors.initials: HL
authors.lastname: Gulseth
authors.forename: Audrey C
authors.initials: AC
authors.lastname: Tierney
authors.forename: Sophie
authors.initials: S
authors.lastname: Morange
authors.forename: Olfa
authors.initials: O
authors.lastname: Helal
authors.forename: Danielle I
authors.initials: DI
authors.lastname: Shaw
authors.forename: Juan A
authors.initials: JA
authors.lastname: Ruano
authors.forename: José
authors.initials: J
authors.lastname: López-Miranda
authors.forename: Beata
authors.initials: B
authors.lastname: Kieć-Wilk
authors.forename: Iwona
authors.initials: I
authors.lastname: Gołąbek
authors.forename: Ellen E
authors.initials: EE
authors.lastname: Blaak
authors.forename: Wim H M
authors.initials: WH
authors.lastname: Saris
authors.forename: Christian A
authors.initials: CA
authors.lastname: Drevon
authors.forename: Julie A
authors.initials: JA
authors.lastname: Lovegrove
authors.forename: Helen M
authors.initials: HM
authors.lastname: Roche
authors.forename: Samar
authors.initials: S
authors.lastname: Basu
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000378:metabolism; D002097:C-Reactive Protein / Q000378:metabolism*; D018752:Diet, Fat-Restricted; D004040:Dietary Carbohydrates / Q000008:administration & dosage; D004041:Dietary Fats / Q000008:administration & dosage*; D019587:Dietary Supplements; D015237:Dinoprost / Q000031:analogs & derivatives / Q000652:urine*; D004797:Enzyme-Linked Immunosorbent Assay; D005227:Fatty Acids / Q000494:pharmacology* / Q000627:therapeutic use; D005247:Feeding Behavior; D005260:Female; D006801:Humans; D007249:Inflammation / Q000178:diet therapy / Q000378:metabolism*; D008297:Male; D024821:Metabolic Syndrome / Q000178:diet therapy / Q000378:metabolism*; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*
chemical_list: D015415:Biomarkers; D004040:Dietary Carbohydrates; D004041:Dietary Fats; D005227:Fatty Acids; D002097:C-Reactive Protein; D015237:Dinoprost